420 with CNW — Can Tenants Smoke Marijuana Within Rental Properties?

Twenty-one states now allow their residents to purchase, possess and consume recreational cannabis while 37 states have medical marijuana programs. Millions of people now have access to cannabis for either medical or recreational purposes, but both state and federal laws prevent public consumption of marijuana. As a result, most people consume cannabis at home.

States laws that decriminalized cannabis allowed people to possess, grow and smoke cannabis in private residences including rental properties. While this isn’t a big issue for products such as edibles, extracts and creams, smoking at home can be a contentious issue, especially for people who are renting their homes.

As more states have legalized private cannabis consumption, there has been an increase in complaints from neighbors and landlords about tenants smoking at home.

In January, a 76-year-old Washington, DC, resident sued the District of Columbia over the smell of cannabis regularly wafting into her home. However, she may not have any legal recourse as private cannabis smoking is allowed by Washington, DC, state law.

If a landlord discovers that a tenant is smoking cannabis, they cannot terminate their lease based on that fact alone if they did not explicitly ban smoking in the rental agreement. On the other hand, a tenant cannot smoke cannabis in their home if their rental agreement stated that smoking on the property wasn’t allowed. If such a tenant smokes cannabis indoors, their actions will constitute a breach of contract, and their landlord will have a solid legal basis to terminate the lease.

The landlord will first be required to provide the tenant with three consecutive written warnings instructing them to stop smoking. After the third warning is issued, the landlord can cancel the lease agreement and give their tenant notice to vacate.

If you smoke cannabis or plan to smoke in the future, make sure your landlord has not included provisions banning indoor smoking in the rent agreement.

Additionally, note that even if your home is deemed a smoking unit, you will be required to prevent your smoking from damaging the home. You may also have to pay for any damage to the property caused by smoking to restore it to its condition before you moved in. This damage includes discolored walls or carpets that smell of marijuana and will need repainting and carpet cleaning or replacing to mitigate.

To keep yourself protected, make sure you review your rent agreement carefully and opt for a unit that allows smoking. Furthermore, you will want to take steps and prevent your smoking from damaging the home to reduce your costs when your lease elapses.

For patients who look to marijuana for therapeutic purposes, a less contentious option could soon be available if entities such as India Globalization Capital Inc. (NYSE American: IGC) succeed in getting FDA approval and commercializing formulations targeting different health complications.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Why It’s Still Hard for Medicare to Cover Medical Cannabis

Even though many seniors use medical cannabis to treat a range of conditions, experts say it may take some time before Medicare begins to pay for the drug because of conflicting legal requirements, ambiguous safety standards and challenging rulemaking procedures. According to a survey conducted last year by the Medicare Plans Resource Center, an association that offers advice and information on Medicare, one in every five Medicare patients uses medical cannabis.

Furthermore, almost 25% have previously used it, and two-thirds of Medicare beneficiaries believe that the program ought to cover it. However, Medicare doesn’t, since medical cannabis is not legal in all states and has not received FDA approval. According to a study that was published in the Cannabinoid and Cannabis Research journal in April last year, 60% of patients who purchased medical cannabis were 50 years of age or older.

Patients often pay up to $20 per gram for cannabis plant buds and $5 per dose for edibles. This amounts to about $567 and $142 per ounce, respectively, a price most patients, even in states where medical cannabis is legal, cannot afford.

Why, then, does Medicare still not cover medical marijuana?

Medicare coverage for medical marijuana is obstructed by two major problems. For starters, the DEA classifies cannabis as a Schedule I drug, meaning it has a high potential for abuse and no currently accepted medical use.

Second, for a drug to be covered by Medicare, it must receive FDA clearance for both safety and efficacy. The FDA has authorized the sale of one marijuana-derived product and three synthetic marijuana-related products for prescription use, but it has not authorized the marketing of marijuana for medical use. Considering that medical marijuana is legal in 37 states, could private insurers that provide Medicare Advantage cover it?

That’s unlikely, according to Marijuana Moment senior editor and reporter Kyle Jaeger. Most health insurers will refuse to cover marijuana as long as it is still classified as a schedule I drug, similar to banking institutions that have been hesitant to provide financial services to cannabis businesses.

Additionally, private insurers look to the FDA for directions on which medications to cover. Insurers need data to show that cannabis-based treatments have outcomes that are comparable to, if not superior to, those of the currently available options that they cover. However, this is made difficult due to the open-market dispensary system, where patients are allowed to purchase any product.

The system will need to be altered for it to be effective; patients cannot simply buy anything they want and expect insurance companies to cover it.

The contradictions between state cannabis laws and regulations at the federal level are in some way holding back the growth of the cannabis industry together with the affiliated industries that support the marijuana industry. For example, one can only guess at what the growth trajectory of entities such as Advanced Container Technologies Inc. (OTC: ACTX) would have been had marijuana been legal federally.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Finds Link Between Medical Cannabis Legalization, Reductions in Payments for Opioids

Dozens of states now allow their residents to use medical cannabis to alleviate more than 20 qualifying medical conditions. Although the research on cannabis is still relatively new, there is strong proof that cannabis-based treatments can alleviate the symptoms of a wide variety of medical conditions.

As a result, millions of Americans across the country now use medical cannabis to treat conditions such as chronic pain, insomnia, anxiety disorders and others. One of the most common uses of medical cannabis is to treat chronic pain, a condition that is estimated to affect an estimated 50.2 million adults in America.

With more and more people turning to cannabis to alleviate their medical conditions, researchers have noted that they are using fewer pharmaceutical opioids. In a new study from the University of Southern California, Purdue University and the University of Florida, researchers said that there has been a significant reduction in direct payments from opioid producers to physicians.

The researchers found that clinicians in states with medical marijuana programs are prescribing fewer opioids to their patients. They used a new “penalized synthetic control model” to review transaction data on direct payments to physicians from opioid manufacturers between 2014 to 2017. Their aim was to determine if there was a causal relationship between the launch of medical marijuana markets and reductions in payments for opioids.

They found evidence indicating that the presence of medical marijuana as an alternative treatment contributed to the reduced payments to opioid manufacturers. Female clinicians and areas with less affluent and higher concentrations of white, working-age populations saw a higher substitution effect. Opioids have been integral in the treatment of pain for decades, and tens of millions of people across the world have used them to manage pain disorders.

Direct payments to physicians help manufacturers to spread their reach and access more customers for their products. However, opioids aren’t always effective, and they have a significant risk of causing side effects such as nausea, constipation and respiratory depression. They can also lead to physical dependence and contribute to the development of opioid use disorder, which affects more than 15 million people globally and causes more than 120,000 deaths across the world annually.

As a result, plenty of chronic pain patients have adopted cannabis as an alternative treatment in place of conventional pharmaceuticals. This study adds to a growing body of literature indicating that more patients are choosing medical cannabis over opioids to manage chronic pain.

Given that chronic pain is a major affliction in the United States and around the world, enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are focused on coming up with cannabis-based therapeutic formulations, which can be approved by the FDA for use against this clinical indication that often compromises the quality of life of the people diagnosed with it.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Studies Link Cannabis Legalization to Various Public Health Benefits

With medical marijuana legalized in 36 states and recreationally approved in 18, worries about the effects of widespread societal access to cannabis have become the driving force behind a majority of scientific research. A large portion of that scientific research has now been compiled in a meta-analysis of 36 papers released between 2013 and 2021. These studies show how legalizing cannabis has had a positive impact on society in significant ways.

Researchers who studied the societal effects of legalizing marijuana discovered that it reduced rates of teen cannabis use, binge drinking, suicide and traffic fatalities.

One main concern has come from conservative politicians and parents who believe that legalizing would result in a rise in teen marijuana use. This criticism perfectly illustrates the idea advanced by author Jonathan Haidt in his seminal book, “The Righteous Mind.” According to the book, most people form their opinions by first coming to an emotional conclusion, such as teenage cannabis use is bad, and then working backward through ad hoc justification to find whatever intuitive reasoning is required to support their instinct.

It would seem reasonable to assume that cannabis use would increase if it were legal, but this isn’t the case. In actuality, the landmark paper revealed that teenagers’ access to marijuana declined by 8% while teenage use decreased by 9% due to legalization. The cause was thought to be that fewer teenagers were able to access the substance once dispensaries replaced drug dealers; the legal requirement to check a buyer’s ID when purchasing cannabis also likely impacted the numbers.

In another study, it was discovered that legalizing cannabis had a negative impact on opioid overdose deaths from 1999 to 2010, but the effect diminished once the years 2011 to 2017 were taken into account. This was thought to be an indication of how the opioid epidemic has evolved, based on the idea that cannabis and prescription painkillers might be substitutes for opioids, but heroin and cannabis are not.

However, this isn’t the only study to establish a link between the legalization of cannabis and a decline in opioid overdoses. Two additional studies found the same thing, with the second finding a drop from 21% to 16% in 2019 and 2020.

Another study found that legalizing cannabis discourages and reduces the use of alcohol, particularly binge drinking. The decline in alcohol consumption may have also significantly reduced the number of road accidents.

Last but not least, marijuana legalization was also associated with lower rates of male suicide across the nation, with an 11% decrease in those 20 to 29 years of age and a 9% decrease in those 30 to 39 years of age.

As all these benefits are being documented, a strong ancillary industry made up of entities such as Advanced Container Technologies Inc. (OTC: ACTX) is thriving due to the market they have carved out for themselves among marijuana industry actors.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New York Medical Marijuana Companies Sue State Regulators Over Licensing Implementation

A coalition of medical marijuana companies in New York is suing state cannabis regulators over licensing implementation provisions that prioritized social equity applicants. Most states with legal cannabis markets have included social equity and justice provisions that seek to compensate members of communities that were disproportionately affected by cannabis prohibition. In cases such as New York, this involved giving people with certain prior cannabis criminal records or their relatives priority access to the license application pool.

The Coalition for Access to Regulated & Safe Cannabis argued in its lawsuit that cannabis regulators overstepped their legal authority by limiting the initial applications to a limited amount of applicants instead of allowing the entire market to apply. The New York Office of Cannabis Management and the Cannabis Control Board as well as several top officials were named in the suit.

New York was a late entrant into the cannabis market and is still working to get its cannabis industry off the ground. The state has currently awarded 66 dispensaries with retail licenses, and the state’s fifth store opened its doors to customers this week.

According to a coalition spokesperson, companies represented by the trade association, including Acreage Holdings, Green Thumb Industries and Curaleaf, have been unable to enter the recreational cannabis market because of the state’s limited licensing program. A memo filed with the suit states that the regulators “overstepped their rule-making authority” and held back the licensing of hundreds of retail cannabis outlets needed to fulfill customer demand for cannabis and compete with the massive black market for cannabis.

The lawsuit claims that state regulators are putting New Yorkers’ health at risk by limiting the application pool. As with California, New York is also home to a large illicit cannabis market that has made it difficult for the legal market to thrive.

New York cannabis regulators took more than a year after recreational cannabis was legalized to begin awarding retail licenses. In the meantime, significant numbers of illicit sellers sprang up across the state to satisfy cannabis demand that simply couldn’t be met by the legal market.

As the regulated market begins to grow, it will certainly struggle to compete with an illicit market that has had more time to become entrenched and that can sell products at significantly lower price points because black market sellers often skimp on testing and safety requirements to lower their costs.

An Office of Cannabis Management spokesperson did not comment on the lawsuit when asked.

In other news, more enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are focusing on developing pharmaceutical-grade medicines from a number of marijuana constituents such as THC in order to combat the rising cases of chronic pain and other clinical indications.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) GrowPods Could Play Key Role in Farming Future

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, has noted that its innovative controlled environment farms could be key to feeding the world, which is projected to reach a population of 10 billion by the next generation. Such an increase would require a 70% increase in global food production, the United Nations has forecast. With that as a backdrop, controlled environment agriculture offers a potential solution because of its ability to produce high yields in small spaces using little water and no soil. Controlled environment agriculture includes indoor and vertical farming practices such as hydroponics, aeroponics and aquaponics; these practices combine to create sustainable, optimized growing conditions that protecting crops from pests and diseases. Industry experts note that these growing environments have potential to provide access to affordable, high-quality and nutritious food, with one leading research projecting that vertical farming may take over approximately 50% of the leafy green markets in the country. “I believe that it’s possible that vertical farming can take over approximately 50% of leafy green markets in the U.S. and portions of small fruit and tomato markets in 10 years,” said research plant pathologist Dr. Kai-Shu Ling.

To view the full press release, visit https://cnw.fm/lrv72

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called GrowPods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New California Bill to Address THC Level Inflation

Anyone who consumed cannabis in the pre-legalization days will tell you that the drug has gotten progressively stronger over the years. Improvements in breeding and cultivation have allowed cultivars to develop strains with extremely high levels of THC (delta-9 tetrahydrocannabinol), the chemical compound that causes marijuana’s well-known “high.”

With demand for products with high THC levels increasing, cultivars nationwide compete to create the most potent cannabis, resulting in an industry suffused with high-potency goods such as dabs. The proliferation of high-potency cannabis products in America’s state legal market has worried some medical experts, who are concerned that inflated THC levels may increase the risk of developing a substance use disorder.

In California, home to the country’s largest cannabis legal cannabis industry, Assemblymember Reggie Jones-Sawyer has introduced a bill that would address THC level inflation in the state’s massive cannabis industry. Assembly Bill 1610 is a measure meant to increase transparency in cannabis testing and get rid of fraud in the nascent industry.

The bill is sponsored by SC Labs, a cannabis and hemp testing company that provides quality control, compliance and R&D testing service to businesses in the cannabis industry. SC Labs chief compliance officer Josh Wurzer notes that the company is sponsoring Assembly Bill 1610 because it would enhance transparency within the marijuana sector by requiring or allowing randomized product shelf testing or in-person lab audits.

He said that SC Labs has thrown its weight behind the bill because there is no way to weed out bad actors that drag the sector down without increased engagement from the state. As it stands, Wurzer said, the current system is allowing these bad actors to profit over legitimate cannabis companies that are striving to follow product safety and compliance rules.

California’s legal cannabis industry may be large, but it is dwarfed by the illicit marijuana market, which generates nearly double the revenue and deprives the state of billions of dollars in taxes.

Wurzer explained that the illicit market coupled with reduced prices has put a lot of pressure on the legal market, but increasing transparency and trust would bolster the legal markets and help them thrive. The bill would also address the price gouging that has forced consumers to dig deeper into their pockets for supposedly high-THC products.

To get a leg up on their competitors and boost their profits, some labs have taken to overstating the percentage of THC in products in a bid to attract more customers. As a result, consumers pay more for products that contain less THC than indicated and, in some cases, are contaminated with pesticides.

Jones-Sawyer’s bill would prevent this by increasing product-safety requirements for producers and requiring in-person annual audits of labs. According to Jones-Sawyer, the bill will also ensure a supply of high-quality products to the cannabis market and protect the consumers.

Such a law may also result in the use of modern cultivation technologies, such as the indoor grow equipment from Advanced Container Technologies Inc. (OTC: ACTX), to produce higher-quality cannabis that tests verify before it hits store shelves.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Mississippi Farmers Switch from Hemp to Growing Marijuana

Mississippi approved the use of medical cannabis last year after a lengthy legislative debate, though local governments were given the option to reject the initiative. Lincoln County was one of the counties that initially declined to participate in the program.

However, the decision prompted Timothy Gibson and Jason McDonald to take the lead in pushing for the legalization of medical cannabis in the county. The two succeeded in getting the issue on the ballot in August last year when county voters overturned the decision made by local officials.

After the vote, they got to work on starting their own medical cannabis cultivation facility — SADUJA — located in East Lincoln. In December 2022, the facility received a license to cultivate medical cannabis, making it the first in Lincoln County. “We have been cultivating hemp since its legalization in Mississippi,” McDonald said. “We provided hemp to regional stores in the state. People may not have been aware that cannabis was grown here legally prior to the legalization of medical marijuana. It was present and flourishing on the farm.

“I think people are typically afraid of new things,” McDonald continued. “It is essentially the same as what we’ve been doing, but on a larger scale, and we switched from using hemp to using medical cannabis. The plant is the same.”

According to McDonald, the local community has turned its attention to the medical cannabis industry. People should be aware that applying to work at a cannabis cultivation facility is a difficult process. For employment at the tea farm, according to McDonald, he can hire anyone over the age of 16, but for the medical marijuana farm, applicants must be at least 21 years old, citizens without a history of felony convictions, and able to pass a background check.

The medical marijuana bill was a major point of contention within the state’s legislature and between legislators and Governor Tate Reeves, who was persistent in imposing strict restrictions on any measure that emerged. Reeves was particularly worried about how much cannabis a patient could legally obtain. The governor preferred a daily limit of 2.7 grams; however, the bill presented to him and passed by a veto-proof majority, permits patients to purchase up to 3.5 grams up to six times a week.

Following his signing of the bill into law, Reeves stated that while the bill was not the one he would have drafted, legislators who made the final version made major improvements to get the state closer to achieving its ultimate goal.

Worries such as those faced by Reeves could soon be partially addressed if organizations such as India Globalization Capital Inc. (NYSE American: IGC) succeed in bringing to market various formulations targeting the different conditions for which patients are enrolling for medical marijuana in different jurisdictions around the country.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in. Moreover, the further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties,” reads a recent article that contains excerpts from a LabioTech writeup. “Lexaria ticks all these boxes. Its unique technology – DehydraTECH – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023… Lastly, and perhaps most importantly, Lexaria has substantially invested in research and development (‘R&D’), an aspect of its operations that is 100% within its control. According to CEO Chris Bunka, the company has designed its applied R&D to boost its commercial prospects, and this ‘is paying off in spades,’ as it has, among others, ‘yielded almost entirely positive results.’”

To view the full article, visit https://cnw.fm/dikY2

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Drug Delivery Technology Demonstrates Growing List of Potential Applications as Evidenced Through Numerous R&D Programs

DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more
The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs
Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more.

Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and shown improved triglyceride and cholesterol levels (https://cnw.fm/ORSPL). The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (“CBD”), aligned with other study work pointing to CBD’s known anti-inflammatory and antioxidant properties. Lexaria is pleased that relatively low dosages of DehydraTECH-CBD seem to support real improvements in the lab animals’ day-to-day health and find encouragement in the positive findings from its first diabetes study.

In addition to DIAB-A22-1, some of Lexaria’s previous R&D programs include:

HYPER-A21-1 – a rodent study demonstrating significant enhancement in CBD delivery using DehydraTECH with more CBD delivered into the bloodstream and brain tissue
HYPER-A21-2 – a rodent study demonstrating the strongest CBD absorption results ever recorded
HYPER-H21-1 – Human clinical study evidencing a rapid and sustained drop in blood pressure with excellent tolerability using DehydraTECH-CBD
HYPER-H21-2 – Human clinical Hypoxic Pulmonary Vasoconstriction study with evidence of up to a 23% decrease in blood pressure confirming a reduction in arterial stiffness
HYPER-H21-3 – Human clinical Pulmonary Hypertension Clinical Study intended to support Lexaria’s plan to seek FDA approvals
HYPER-H21-4 – Human clinical study exhibiting exceptional safety and tolerability with statistically significant evidence of lowered blood pressure in patients and showed great absorption levels and potential novel mechanism of action in reducing blood pressure
VIRAL-C21-3 – In vitro screening assay completed using primate cell line, VERO-E6, determining that remdesivir and ebastine processed with DehydraTECH were effective in inhibiting the COVID-19 virus
VIRAL-A20-2 – A rodent study showing a three-fold increase in oral delivery of anti-viral drugs
VIRAL-MC21-1 – research concluded that DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity or change in chemical structure
VIRAL-A20-3 – A rodent study demonstrating significant enhancement in anti-viral drug delivery using DehydraTECH-enabled Colchicine with possible benefits of treating COVID-19 and mRNA vaccine side effects
NIC-A21-1 – DehydraTECH-oral nicotine delivery peaked in the bloodstream 10x and 20x faster than controls, with peak levels achieved 10x higher than controls
PDE5-A21-1 – DehydraTECH-sildenafil delivered 74% more drug at 4 minutes than the control
EPIL-A21-1 – DehydraTECH-CBD has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R)

Since 2014, Lexaria has been developing its patented DehydraTECH technology, which has yielded 28 granted patents and many more pending in countries worldwide. DehydraTECH’s evidenced benefits include the improved speed of onset, increased bioavailability, increased brain absorption, and reduced drug administration costs. As more research becomes available from Lexaria’s ongoing R&D programs, the company will provide updates.

Lexaria operates four subsidiary companies, focusing on different commercial opportunities in their respective industries:

Lexaria Pharmaceutical Corp. investigates new products for hypertension, antiviral treatments, epilepsy, some pharmaceutical applications of nicotine and other drug classes
Lexaria Nicotine LLC investigates oral non-combusted tobacco-derived nicotine product formats
Lexaria Hemp Corp. pursues business-to-business opportunities with cannabinoids
Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization

Lexaria sub-licenses the company’s DehydraTECH technology for the delivery of fat-soluble active molecules and drugs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.